 |
|
Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
September 09, 2005A new drug may help cancer patients mobilize the cells necessary to restore their blood-forming system after high-dose chemotherapy, according to results from a clinical trial at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia and at other centers across the nation.
In the phase II trial, researchers were attempting to determine if patients with multiple myeloma or non-Hodgkin's lymphoma who received the drug AMD-3100 along with the standard drug G-CSF (granulocyte-colony stimulating factor) would have more stem cells available for transplantation.
AMD-3100 blocks a specific cellular receptor, triggering the movement of stem cells out of the bone marrow and into the circulating blood, boosting the supply of marrow stem cells available for transplantation. Stem cell transplantation entails collecting certain types of cells known as hematopoietic stem cells from patients who receive treatment with high-dose radiation and/or chemotherapy for cancers such as leukemias, lymphomas and multiple myeloma, all of which involve the blood and immune system. The cells, once returned to the body, help restore the blood-forming system within the bone marrow - and the body's immune system, which is severely damaged if not destroyed by treatment.
Stem cell transplantation is considered "front-line therapy for multiple myeloma, or cancer of the bone marrow, and for high-risk leukemia and lymphoma patients," says Neal Flomenberg, M.D., professor of medicine and director of medical oncology at Jefferson Medical College of Thomas Jefferson University, who led the trial at Jefferson.
The researchers found that all of the 25 patients (10 patients with multiple myeloma and 15 patients with non-Hodgkin's lymphoma) given the drug combination could move enough cells from the marrow to the bloodstream compared to only 64 percent of those who had G-CSF alone. They report their results September 1, 2005 in the journal Blood.
As a result, Dr. Flomenberg says, there were fewer stem cell collections necessary and more stem cells retrieved. The greater the number of available stem cells, the more likely transplantation will be successful. In some cases, this can mean the difference between a patient being able to receive a transplant or not. The drug has little toxicity.
"One of the most important results from the trial was that nine patients who would not have been able to mobilize stem cells to go to transplant with G-CSF alone could now mobilize them with the combination of G-CSF and AMD-3100," Dr. Flomenberg says.
In addition, some patients who received AMD-3100 needed fewer stem cell collections to get the necessary number of cells, making the overall process less taxing. Those who still required the same number of collections had a higher total of stem cells.
"It's hoped that the drug combination will make white cell and platelet recovery quicker and allow patients who wouldn't have otherwise been able to mobilize stem cells for transplant now be able to do so," he says. Without adequate numbers of stem cells for transplantation, patients may have a delayed recovery of their immune systems and be at greater risk of infection.
Most patients undergo standard chemotherapy for four to eight months before they have a stem cell transplant, he explains. Some patients won't have a transplant until their disease relapses and treatment once again puts them back in remission. These treatments sometimes make subsequent stem cell collection difficult.
Approximately 25 percent to 35 percent of transplant patients - and perhaps as many as 65 percent - have trouble moving optimal numbers of stem cells from their bone marrow into the bloodstream using G-CSF. "Some patients with the standard approach don't mobilize well, meaning more collections and often a poor or unusable cell product," he says.
Dr. Flomenberg believes that the drug combination will become a standard treatment for such cases involving stem cell transplantation. "The treatment has potential to alter the standard of practice," he says.
Researchers currently are conducting two phase III trials comparing G-CSF and placebo to G-CSF and AMD-3100 in 600 patients with either non-Hodgkin's lymphoma or multiple myeloma, he notes. Jefferson is participating in both trials, in addition to another phase II trial with AMD-3100 alone.
The research is sponsored by AnorMED, Inc., a Vancouver, British Columbia-based drug development company. AnorMED's efforts are aimed at the discovery and development of small molecule therapeutics to treat diseases including HIV, rheumatoid arthritis, asthma and cancer.
Thomas Jefferson University Hospital
Stem cell transplantation is considered "front-line therapy for multiple myeloma, or cancer of the bone marrow, and for high-risk leukemia and lymphoma patients," says Neal Flomenberg, M.D., professor of medicine and director of medical oncology at Jefferson Medical College of Thomas Jefferson University, who led the trial at Jefferson.
The researchers found that all of the 25 patients (10 patients with multiple myeloma and 15 patients with non-Hodgkin's lymphoma) given the drug combination could move enough cells from the marrow to the bloodstream compared to only 64 percent of those who had G-CSF alone. They report their results September 1, 2005 in the journal Blood.
As a result, Dr. Flomenberg says, there were fewer stem cell collections necessary and more stem cells retrieved. The greater the number of available stem cells, the more likely transplantation will be successful. In some cases, this can mean the difference between a patient being able to receive a transplant or not. The drug has little toxicity.
"One of the most important results from the trial was that nine patients who would not have been able to mobilize stem cells to go to transplant with G-CSF alone could now mobilize them with the combination of G-CSF and AMD-3100," Dr. Flomenberg says.
In addition, some patients who received AMD-3100 needed fewer stem cell collections to get the necessary number of cells, making the overall process less taxing. Those who still required the same number of collections had a higher total of stem cells.
"It's hoped that the drug combination will make white cell and platelet recovery quicker and allow patients who wouldn't have otherwise been able to mobilize stem cells for transplant now be able to do so," he says. Without adequate numbers of stem cells for transplantation, patients may have a delayed recovery of their immune systems and be at greater risk of infection.
Most patients undergo standard chemotherapy for four to eight months before they have a stem cell transplant, he explains. Some patients won't have a transplant until their disease relapses and treatment once again puts them back in remission. These treatments sometimes make subsequent stem cell collection difficult.
Approximately 25 percent to 35 percent of transplant patients - and perhaps as many as 65 percent - have trouble moving optimal numbers of stem cells from their bone marrow into the bloodstream using G-CSF. "Some patients with the standard approach don't mobilize well, meaning more collections and often a poor or unusable cell product," he says.
Dr. Flomenberg believes that the drug combination will become a standard treatment for such cases involving stem cell transplantation. "The treatment has potential to alter the standard of practice," he says.
Researchers currently are conducting two phase III trials comparing G-CSF and placebo to G-CSF and AMD-3100 in 600 patients with either non-Hodgkin's lymphoma or multiple myeloma, he notes. Jefferson is participating in both trials, in addition to another phase II trial with AMD-3100 alone.
The research is sponsored by AnorMED, Inc., a Vancouver, British Columbia-based drug development company. AnorMED's efforts are aimed at the discovery and development of small molecule therapeutics to treat diseases including HIV, rheumatoid arthritis, asthma and cancer.
Thomas Jefferson University Hospital
Stem Cells News and Current Stem Cells Events RSSTAU Researchers Create New Stem Cell Screening Tool
Stem cell research is the next great leap in medicine. In the future, new tissue grown in a laboratory could replace a failing heart, or new cells take the place of damaged cells in the brain.
NC State Is First University in Nation to Offer Canine Bone Marrow Transplants
Dogs suffering from lymphoma will be able to receive the same type of medical treatment as their human counterparts, as North Carolina State University becomes the first university in the nation to offer canine bone marrow transplants in a clinical setting.
Hearing restoration may be possible with cochlear repair after transplant of human cord blood cells
According to an Italian research team publishing their findings in the current issue of Cell Transplantation (17:6), hearing loss due to cochlear damage may be repaired by transplantation of human umbilical cord hematopoietic stem cells (HSC) since they show that a small number migrated to the damaged cochlea and repaired sensory hair cells and neurons.
Cardiac cell transplant studies show promise in cardiac tissue repair
Two studies published in the current issue of CELL TRANSPLANTATION (17:6) examine the efficacy of transplanting bone marrow cells (BMCs) for the repair of heart tissue.
Stem cell research puts interstate rivalry on hold
Victoria and New South Wales have put aside their competitive interstate rivalry to collaborate on a stem cell research project, as announced by Innovation Minister Gavin Jennings and NSW Minister for Science and Medical Research, Verity Firth, today.
Blood vessel cells are instructed to form tube-like structures
How do blood vessel cells understand that they should organise themselves in tubes and not in layers? A research group from Uppsala University shows for the first time that a special type of "instructor" molecule is needed to accomplish this. These findings, published in the scientific journal Blood, might be an important step towards using stem cells to build new organs.
Antidepressants need new nerve cells to be effective, researchers find
Researchers at UT Southwestern Medical Center have discovered in mice that the brain must create new nerve cells for either exercise or antidepressants to reduce depression-like behavior.
Antidepressants need new nerve cells to be effective, UT Southwestern researchers find
Researchers at UT Southwestern Medical Center have discovered in mice that the brain must create new nerve cells for either exercise or antidepressants to reduce depression-like behavior.
Alcohol consumption can cause too much cell death, fetal abnormalities
The initial signs of fetal alcohol syndrome are slight but classic: facial malformations such as a flat and high upper lip, small eye openings and a short nose.
Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body
Magnetic resonance imaging (MRI) isn't just for capturing detailed images of the body's anatomy. Thanks to novel imaging reagents and technology developed by Carnegie Mellon University scientist Eric Ahrens, MRI can be used to visualize - with "exquisite" specificity - cell populations of interest in the living body.
More Stem Cells News Articles
 | My Sister's Keeper: A Novel by Jodi Picoult New York Times bestselling author Jodi Picoult is widely acclaimed for her keen insights into the hearts and minds of real people. Now she tells the emotionally riveting story of a family torn apart by conflicting needs and a passionate love that triumphs over human weakness.Anna is not sick, but she might as well be. By age thirteen, she has undergone countless surgeries, transfusions, and shots... |
 | Embryo: A Defense of Human Life by Robert P. George, Christopher Tollefsen The bitter national debates over abortion, euthanasia, and stem cell research have created an unbridgeable gap between religious groups and those who insist that faith-based views have no place in public policy. Religious conservatives are so adamantly opposed to stem cell research in particular that President Bush issued the first veto of his presidency over a bill that would have provided... |
 | Sex, Science, and Stem Cells by Diana DeGette In August 2001, President George W. Bush announced with fanfare that federal funds would be made available to scientists conducting research on human embryonic stem cell lines—with restrictions. Reading his words, not his lips, was Congresswoman Diana DeGette of Colorado’s First Congressional District, and what she read was this: a ban. “As a practical matter,” scientists... |
 | The Oxygen Revolution: Hyperbaric Oxygen Therapy: The Groundbreaking New Treatment for Stroke, Alzheimer's, Parkinson's, Arthritis, Autism, Learning Disabilities and More by Paul G. Harch, Virginia Mccullough HOPE FOR MANY "HOPELESS" DISEASES, FROM ONE OF THE FOREMOST RESEARCHERS IN THE FIELDWhen Randy McCloy, Jr., the sole survivor of the Sago Mine disaster, finally walked out of the hospital to rejoin his family, it was in part due to the miracle of hyperbaric oxygen therapy. Hyperbaric oxygen therapy (HBOT) is based on an almost laughably simple idea: Oxygen can be used therapeutically for a wide... |
 | Miracle Stem Cell Heart Repair: (For Heart Attack, Heart Failure and Bypass Patients) by Christian Wilde |
 | Irreparable Harm by Randy D. Singer A fight for life. A battle for right.Attorney Mitchell Taylor is trapped in a lose-lose situation.Bright but inexperienced attorney Mitchell Taylor is torn between warring personal and professional interests. Can he help his client–a young surrogate mother–and save the child she carries without sealing the fate of others? The compelling answer lies in Randy Singer’s new legal... |
 | Fundamentals of the Stem Cell Debate: The Scientific, Religious, Ethical, and Political Issues Few recent advances in science have generated as much excitement and controversy as human embryonic stem cells. The potential of these cells to replace diseased or damaged cells in virtually every tissue of the body heralds the advent of an extraordinary new field of medicine. Controversy arises, however, because current techniques required to harvest stem cells involve the destruction of the... |
 | Essentials of Stem Cell Biology This abridged version of the bestselling reference Handbook of Stem Cells, Two-Volume Set attempts to incorporate all the essential subject matter of the original two-volume edition in a single volume. The material has been reworked in an accessible format suitable for students and general readers interested in following the latest advances in stem cells, including full color presentation... |
 | Bioethics as Practice (Studies in Social Medicine) by Judith Andre Those who work in bioethics and the medical humanities come from many different backgrounds, such as health care, philosophy, law, the social sciences, and religious studies. The work they do also varies widely: consulting on ethical issues in patient care, working with legislatures, dealing with the media, teaching, speaking, writing, and more. Writing as a participant in this field, Judith... |
 | The Stem Cell Controversy: Debating the Issues (Contemporary Issue Series) Stem cell research is headline news. Researchers are eager to move forward, state governments and private foundations are rushing to support it, and the sick and afflicted are desperate for its benefits. Yet powerful forces in our society—led by President George W. Bush—find it morally troubling and they are doing all in their powers to restrict its development beyond a very limited... |
| © 2008 BrightSurf.com |